Pfizer CEO Read hasn't given up on tax inversion deals; Novartis' Diovan loss is Ranbaxy Labs' quarterly gain;

@FiercePharma: Tops in FierceAnimalHealth: Lilly divests U.S. animal health assets to Virbac ahead of Novartis deal. Story | Follow @FiercePharma

@EricPFierce: Ranbaxy's New Jersey plant comes through for drugmaker. More | Follow @EricPFierce

@CarlyHFierce: Our newest special report is live! Pharma's top 10 M&A deals of H1 2014. Feature | Follow @CarlyHFierce

> Pfizer ($PFE) CEO Ian Read says he hasn't given up on scoring a tax inversion deal, even with new U.S. rules designed to limit them; on a case-by-case basis, some might offer "meaningful value." Report

> India's generics maker Ranbaxy Laboratories posted its first profit since 2012, thanks to its generic version of the Novartis ($NVS) blood pressure med Diovan. Report

> India-based Lupin reported a 54% leap in quarterly profits, which beat analyst estimates; U.S. sales helped fuel revenue growth. Report

> Sanofi ($SNY) said it had started producing generic drugs in United Arab Emirates via Globalpharma, a UAE company now 66% owned by the French drugmaker. Report

Medical Device News

@FierceMedDev: IPOs: Sientra goes for $75M, while Nevro nerves up for $100M. Report | Follow @FierceMedDev

@VarunSaxena2: Here's my pernicious article. Read it are your own risk. ICYMI yesterday | Follow @VarunSaxena2

@EmilyWFierce: Find out which companies struck gold in the pharma M&A frenzy in FiercePharma's latest special report. Report | Follow @EmilyWFierce

> HealthTrust commits to buying Infraredx coronary imaging tech. Item

> Welch Allyn partners with startup Gentag to create wearable devices. More

> Wright, Tornier merge in $3.3B inversion deal to create extremities and biologics pure play. News

Biotech News

@FierceBiotech: $AMGN, $SNY and Ono band together for open-source R&D. Article | Follow @FierceBiotech

@JohnCFierce: Amgen adds up to 1,100 new job cuts to its global restructuring plan - Wall Street loves it, shares up 5%. News | Follow @JohnCFierce

@DamianFierce: $RNA CEO on $SRPT's setback: "We are all in this together." More from CNBC | Follow @DamianFierce

@EmilyMFierce: Salk's 100th: Anti-Vaccination Would Trouble Polio Hero. More from LiveScience | Follow @EmilyMFierce

> Novartis chief Jimenez predicts 'multi-blockbuster' success for star heart drug. Article

> Advent joins the parade of new biotech funds with $235M war chest. Item

> Receptos' lead drug scores another promising PhII--this time for ulcerative colitis. News

> Bristol-Myers nabs a HER2 cancer drug in $475M option deal with F-star. Report

Biotech Research News

> Government halts research on dangerous airborne pathogens. Item

> Toxin-producing stem cells designed to kill brain cell tumors. Report

> Brain cells reprogrammed from skin cells offer treatment hope for Huntington's. Story

> Case Western, Janssen, Oncodesign scientists ID anti-inflammatory compounds. More

> Protein discovery could help kill stubborn latent HIV. Article

Pharma Manufacturing News

> Australia's CSL gets three Novartis vaccine plants in $275M deal. News

> Ranbaxy's New Jersey plant comes through for drugmaker. Item

> Hikma gets FDA warning letter for plant in Portugal. More

> Fujifilm adding Texas-based vaccine specialist to its fold. Story

> U.S. Attorney subpoenas Novo for info on Denmark plant. Article

And Finally...The FDA's staff reviewers recommended that Daiichi Sankyo's new blood thinner be approved, but with limits. Report